Horseshoe Crab Blood Holds Life‑Saving Antimicrobial Compound

Horseshoe crabs, long‑living arthropods found along North American coastlines, possess a unique blue blood that is essential to modern medicine. The blood contains a clot‑forming protein, limulus amebocyte lysate (LAL), which detects bacterial endotoxins in vaccines, surgical instruments, and other medical products. Because the LAL test is highly reliable, millions of horseshoe crabs are harvested each year for their blood, a practice that has raised concerns about the sustainability of the species.

Recent studies show that the combined pressures of commercial harvesting, habitat loss, and climate change have led to steep declines in horseshoe crab populations. Conservation groups and lawmakers are now racing to implement protective measures. New regulations in several states restrict the number of crabs that can be collected each season, while research into synthetic LAL alternatives is accelerating. Efforts also focus on preserving critical spawning beaches and mitigating coastal development, aiming to balance the species’ ecological role as a food source for migratory shorebirds with its biomedical value.

The race to protect horseshoe crabs underscores the broader challenge of conserving species that serve both ecological and human health functions. By tightening harvest limits, promoting habitat restoration, and advancing lab‑based endotoxin tests, stakeholders hope to secure the future of these ancient creatures while maintaining the safety standards that rely on their blue blood.